Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 12, 2002. The report details specific corporate actions regarding share re-purchases and changes in director shareholdings, rather than providing comprehensive financial results for a fiscal period.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to specific share transactions:
- Share Re-purchase (Dec 6, 2002): 840,000 Ordinary 25 pence shares purchased for cancellation at 1,170.57 pence per share.
- Share Re-purchase (Dec 11, 2002): 830,000 Ordinary 25 pence shares purchased for cancellation at 1,199.86 pence per share.
- Director Acquisition (Dec 10, 2002): Mr. J.D. Coombe acquired 20 Ordinary Shares (10 personal, 10 company match) at £11.86 per share under the ShareReward Plan.
Material Changes
The filing reports a reduction in the company's outstanding share count due to the cancellation of 1,670,000 shares purchased on December 6 and December 11, 2002. These transactions were executed under authority granted by shareholders at the Annual General Meeting on May 20, 2002. No other material changes to operations or financial position are disclosed in this text.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a notification of recent share transactions and director interest changes.
Investor Verification Checklist
- Verify the total number of shares remaining in the re-purchase authority following the December 6 and 11 transactions.
- Confirm the total cost of the 1,670,000 shares repurchased for cancellation.
- Review the full terms of the ShareReward Plan to understand the matching contribution structure for directors.
- Check subsequent filings for the impact of these share cancellations on earnings per share (EPS).